Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

by | Jun 21, 2024 | Consumer Products, FEATURED, HEADLINE, Investing, Stocks

Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing …

FEATURED